Partnership: Boehringer Ingelheim GmbH
Vitae Pharmaceuticals and Boehringer Ingelheim have partnered to develop novel drugs for the treatment of diabetes and Alzheimer's disease.
11ß-HSD-1 inhibitors for the treatment of diabetes
With BI, we have an exclusive, worldwide strategic partnership to develop and commercialize novel compounds for patients with diabetes and related metabolic disease conditions, such as dyslipidemia, obesity and hypertension. The alliance encompasses multiple series of novel, orally available 11ß-HSD-1 inhibitors discovered by Vitae Pharmaceuticals using our proprietary structure based design platform. Vitae Pharmaceuticals and BI have combined programs and jointly selected compounds for further development. Under the agreement, BI leads and funds development and commercialization of 11ß-HSD-1 inhibitors. Vitae Pharmaceuticals retains the right to develop compounds independently for certain indications outside of the core focus of diabetes and related metabolic conditions. Vitae Pharmaceuticals received an initial cash payment, equity investment, and research funding. In addition, Vitae Pharmaceuticals is eligible to receive up to $300 million in additional payments upon achievement of success-based milestones. Further milestones may be achieved with additional compounds or approved indications. BI also will pay Vitae Pharmaceuticals royalties on the sale of all products related to the program. To date, Vitae Pharmaceuticals has earned $63 million under the collaboration.
Beta secretase (BACE) inhibitors for the treatment of Alzheimer's disease
In June 2009, we established our second strategic alliance with Boehringer Ingelheim (BI) around our beta secretase (BACE) program. Similar to our successful diabetes partnership, this alliance is an exclusive, worldwide strategic collaboration to discover, develop and commercialize novel compounds for the treatment of Alzheimer's disease. Building on Vitae Pharmaceuticals’ rapidly advancing program, BI and Vitae Pharmaceuticals are working jointly to optimize compounds targeting BACE suitable for clinical development. BI will lead the development and commercialization of selected compounds. Under the agreement, Vitae Pharmaceuticals received initial cash and near term payments of $42 million. In addition, Vitae Pharmaceuticals will be eligible to receive $200 million in pre-commercial milestone payments based on the achievement of clinical and regulatory goals, as well as further milestone payments based on potential additional compounds and/or other approved indications. Vitae Pharmaceuticals will receive commercial performance payments and royalties from Boehringer-Ingelheim on all future product sales related to the program.